Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. (Nasdaq: XCUR) on August 7, 2019, reporting events that occurred on August 2, 2019. The filing primarily addresses the appointment of two new directors to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
On August 2, 2019, the Board of Directors appointed two new members:
- Bali Muralidhar, M.D., Ph.D.: Appointed as a Class I director. He is a partner at Abingworth LLP and was recommended by Abingworth and another investor from the Company's recent public offering.
- Bosun Hau: Appointed as a Class III director. He is a Managing Director and Co-Head of Private Equity at Tybourne Capital Management and was also recommended by Abingworth and another investor.
Compensation and Governance Details
Both directors are subject to the Company's standard non-employee director compensation program:
- Cash Retainer: $35,000 annually for each director.
- Stock Options: Each director was granted an option to purchase 43,386 shares of common stock.
- Exercise Price: $2.95 per share (closing market price on August 2, 2019).
- Vesting Schedule: Options vest in equal monthly installments over three years, contingent on continued service.
- Change in Control: Full accelerated vesting occurs upon involuntary termination (other than for cause or for good reason) within 12 months of a change in control.
No other material arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist between the Company and the new directors or their immediate families.
Investor Verification Checklist
- Verify the impact of the new directors' expertise (life sciences investment and private equity) on the Company's strategic direction.
- Review the definitive proxy statement on Schedule 14A (filed April 30, 2019) for the full details of the director compensation program.
- Confirm the vesting status of the 43,386 options granted to each director in future filings.
- Monitor for any future filings regarding the "recently completed public offering" mentioned as the source of the investor recommendations.